A Phase 1 interventional study of Rotigotine transdermal patch in Healthy Volunteers, sponsored by UCB Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-05-22.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of two Rotigotine patches of two different formulations
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
Drug: Rotigotine transdermal patch
Rotigotine transdermal patch 4.5 mg/10 cm\^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm\^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
Drug: Rotigotine transdermal patch
Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
Also known as: Neupro®
AUC(0-tz) of Unconjugated Rotigotine
The AUC(0-tz) is the area under the concentration-time curve from zero up to the last analytically quantifiable concentration.
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Cmax of Unconjugated Rotigotine
The Cmax is the maximum plasma concentration.
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
AUC(0- ∞) of Unconjugated Rotigotine
The AUC(0- ∞) is the area under the plasma concentration-time curve from zero up to infinity
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine
The AUC(0-tz) norm (apparent dose) is the area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
AUC(0-tz) Norm (Body Weight) of Unconjugated Rotigotine
The AUC(0-tz) norm (BW) is the area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
AUC(0- ∞) Norm (Apparent Dose)
The AUC(0-inf) norm (apparent dose) is the area under the plasma concentration-time curve from zero up to infinity normalized by apparent dose (mg).
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
AUC(0- ∞) Norm (Body Weight)
The AUC(0-inf) norm (BW) is the area under the plasma concentration-time curve from zero up to infinity normalized by body weight (kg).
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Cmax, Norm (Apparent Dose) of Unconjugated Rotigotine
The Cmax, norm (apparent dose) is the maximum plasma concentration normalized by apparent dose (mg).
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Cmax, Norm (Body Weight) of Unconjugated Rotigotine
The Cmax, norm (BW) is the maximum plasma concentration normalized by body weight (kg).
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Tmax of Unconjugated Rotigotine
The tmax is the time to reach maximum plasma concentration after patch application.
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Mean Residence Time (MRT) of Unconjugated Rotigotine
The MRT is the mean residence time.
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Rate Constant of Elimination (λz) of Unconjugated Rotigotine
The λz of unconjugated rotigotine is the rate constant of elimination.
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Terminal Half-Life (t1/2) of Unconjugated Rotigotine
the t1/2 of unconjugated rotigotine is the terminal half-life, calculated as t1/2=ln2/ λz.
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Apparent Total Body Clearance (CL/f) of Unconjugated Rotigotine
The CL/f of unconjugated rotigotine is the apparent total body clearance.
Time frame: 0 h (predose), 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h (before patch removal in the morning of Day 2), 25 h, 26 h, 28 h, 30 h, 32 h, 36 h, 40 h, and 48 h
Apparent Dose
Apparent dose of unconjugated rotigotine in mg. The apparent dose was calculated by subtraction of the determined residual content of each rotigotine patch from the nominal content of rotigotine in the patch.
Time frame: 24 hours
A total of 50 healthy, male subjects have been randomized in order to complete the trial with at least 38 subjects qualified for the Pharmacokinetic Set (PKS). Baseline characteristics refer to the PKS which is the primary analysis set.
| Milestone | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First |
|---|---|---|
| Started | 25 | 25 |
| Completed | 24 | 24 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Milestone | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First |
|---|---|---|
| Started | 24 | 24 |
| Completed | 24 | 24 |
| Not completed | 0 | 0 |
| Milestone | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First |
|---|---|---|
| Started | 24 | 24 |
| Pharmacokinetic set (pks) | 18 | 22 |
| Completed | 24 | 24 |
| Not completed | 0 | 0 |
The AUC(0-tz) is the area under the concentration-time curve from zero up to the last analytically quantifiable concentration.
| ng/ mL*h | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| AUC(0-tz) of Unconjugated Rotigotine | 5.2704 ± 3.1435 | 5.4724 ± 2.4755 |
The Cmax is the maximum plasma concentration.
| ng/ mL | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Cmax of Unconjugated Rotigotine | 0.26156 ± 0.15594 | 0.25774 ± 0.11184 |
The AUC(0- ∞) is the area under the plasma concentration-time curve from zero up to infinity
| ng/ mL*h | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| AUC(0- ∞) of Unconjugated Rotigotine | 5.36933 ± 3.17013 | 5.56925 ± 2.49370 |
The AUC(0-tz) norm (apparent dose) is the area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by apparent dose (mg).
| ng/ mL*h/ mg | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| AUC(0-tz) Norm (Apparent Dose) of Unconjugated Rotigotine | 2.56504 ± 0.88171 | 2.66067 ± 1.02321 |
The AUC(0-tz) norm (BW) is the area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration normalized by body weight (kg).
| ng*h*kg/ mL | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| AUC(0-tz) Norm (Body Weight) of Unconjugated Rotigotine | 412.942 ± 239.918 | 434.101 ± 206.274 |
The AUC(0-inf) norm (apparent dose) is the area under the plasma concentration-time curve from zero up to infinity normalized by apparent dose (mg).
| ng/ mL*h/ mg | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| AUC(0- ∞) Norm (Apparent Dose) | 2.62042 ± 0.88891 | 2.71397 ± 1.03223 |
The AUC(0-inf) norm (BW) is the area under the plasma concentration-time curve from zero up to infinity normalized by body weight (kg).
| ng*h*kg/ mL | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| AUC(0- ∞) Norm (Body Weight) | 420.811 ± 242.327 | 441.761 ± 207.793 |
The Cmax, norm (apparent dose) is the maximum plasma concentration normalized by apparent dose (mg).
| ng/ mL/ mg | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Cmax, Norm (Apparent Dose) of Unconjugated Rotigotine | 0.128863 ± 0.045903 | 0.126144 ± 0.046104 |
The Cmax, norm (BW) is the maximum plasma concentration normalized by body weight (kg).
| ng/ mL*kg | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Cmax, Norm (Body Weight) of Unconjugated Rotigotine | 20.4935 ± 11.9380 | 20.4489 ± 9.3456 |
The tmax is the time to reach maximum plasma concentration after patch application.
| hours (h) | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Tmax of Unconjugated Rotigotine | 16.78 ± 5.23 | 15.75 ± 5.24 |
The MRT is the mean residence time.
| hours (h) | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Mean Residence Time (MRT) of Unconjugated Rotigotine | 18.473 ± 1.936 | 18.186 ± 2.056 |
The λz of unconjugated rotigotine is the rate constant of elimination.
| 1/ h | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Rate Constant of Elimination (λz) of Unconjugated Rotigotine | 0.162587 ± 0.033663 | 0.165400 ± 0.033405 |
the t1/2 of unconjugated rotigotine is the terminal half-life, calculated as t1/2=ln2/ λz.
| hours (h) | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Terminal Half-Life (t1/2) of Unconjugated Rotigotine | 4.4523 ± 0.9701 | 4.3752 ± 0.9677 |
The CL/f of unconjugated rotigotine is the apparent total body clearance.
| L/ h | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Apparent Total Body Clearance (CL/f) of Unconjugated Rotigotine | 1125.11 ± 621.56 | 1041.47 ± 640.57 |
Apparent dose of unconjugated rotigotine in mg. The apparent dose was calculated by subtraction of the determined residual content of each rotigotine patch from the nominal content of rotigotine in the patch.
| mg | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| Apparent Dose | 1.970 ± 0.637 | 2.036 ± 0.597 |
Collected over Adverse Events were collected up to 14 days after the last patch removal.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine PR2.2.1 | — | 0/49 (0%) | 23/49 (46.9%) |
| Rotigotine PR2.1.1 | — | 0/49 (0%) | 26/49 (53.1%) |
| Event | Rotigotine PR2.2.1 | Rotigotine PR2.1.1 |
|---|---|---|
| FatigueGeneral disorders | 6/49 | 4/49 |
| Application Site PruritusGeneral disorders | 4/49 | 5/49 |
| HeadacheNervous system disorders | 2/49 | 5/49 |
| DizzinessNervous system disorders | 5/49 | 4/49 |
| NauseaGastrointestinal disorders | 4/49 | 2/49 |
| SomnolenceNervous system disorders | 4/49 | 0/49 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 4/49 | 2/49 |
| Lipase IncreasedInvestigations | 0/49 | 3/49 |
| VomitingGastrointestinal disorders | 2/49 | 1/49 |
| DyspepsiaGastrointestinal disorders | 2/49 | 0/49 |
| Age Continuous(years) | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First | Total |
|---|---|---|---|
| Mean | 37.1 ± 12.6 | 35.6 ± 9.6 | 36.3 ± 11.0 |
| Sex: Female, Male(Participants) | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 18 | 22 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 18 | 22 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 18 | 22 | 40 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First | Total |
|---|---|---|---|
| Mean | 24.42 ± 2.71 | 24.16 ± 2.75 | 24.28 ± 2.70 |
| Height(meter (m)) | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First | Total |
|---|---|---|---|
| Mean | 1.807 ± 0.083 | 1.807 ± 0.058 | 1.807 ± 0.069 |
| Weight(kilogramm (kg)) | Rotigotine PR2.2.1 First | Rotigotine PR2.1.1 First | Total |
|---|---|---|---|
| Mean | 79.94 ± 11.74 | 78.88 ± 9.14 | 79.36 ± 10.26 |
The record gives a start of Jan 2010, a primary completion of Feb 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine